These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nilika Shah Singhal, MD, and Kendall B. Nash, MD. Greer DM Semin Neurol; 2020 Apr; 40(2):173-174. PubMed ID: 32268413 [No Abstract] [Full Text] [Related]
3. Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model. Li C; Ye J; Peng Y; Dou W; Shang S; Wu J; Jafari R; Gillen KM; Wang Y; Prince M; Luo X Magn Reson Imaging; 2019 Nov; 63():267-273. PubMed ID: 31445117 [TBL] [Abstract][Full Text] [Related]
4. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. Harrison SA; Dennis A; Fiore MM; Kelly MD; Kelly CJ; Paredes AH; Whitehead JM; Neubauer S; Traber PG; Banerjee R PLoS One; 2018; 13(9):e0203054. PubMed ID: 30192782 [TBL] [Abstract][Full Text] [Related]
5. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Harrison SA; Marri SR; Chalasani N; Kohli R; Aronstein W; Thompson GA; Irish W; Miles MV; Xanthakos SA; Lawitz E; Noureddin M; Schiano TD; Siddiqui M; Sanyal A; Neuschwander-Tetri BA; Traber PG Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1183-1198. PubMed ID: 27778367 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Wang H; Wang L; Cheng Y; Xia Z; Liao Y; Cao J Biomed Rep; 2018 Jul; 9(1):90-96. PubMed ID: 29930810 [TBL] [Abstract][Full Text] [Related]
8. Minimisation of salicylate interference in the Glynn and Kendal paracetamol procedure. Longlands MG; Wiener K Ann Clin Biochem; 1982 May; 19(3):187-90. PubMed ID: 7092146 [TBL] [Abstract][Full Text] [Related]
12. 60 seconds with Sarah Kendal. Kendal S Nurs Times; 2013 Apr 2-8; 109(13):26. PubMed ID: 23621083 [No Abstract] [Full Text] [Related]
13. Topographical Pathology of Kendal and Its Neighbourhood. Proudfoot T Edinb Med Surg J; 1822 Jul; 18(72):374-393. PubMed ID: 30332041 [No Abstract] [Full Text] [Related]
14. Account of the Epidemic Cholera of Kendal. Proudfoot T Edinb Med Surg J; 1833 Jan; 39(114):70-103. PubMed ID: 30330483 [No Abstract] [Full Text] [Related]
15. Dr. Kendal Franks on Mr. Burdett Coutts's Charges. Br Med J; 1900 Sep; 2(2070):602-3. PubMed ID: 20759167 [No Abstract] [Full Text] [Related]
16. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. Maurice JB; Patel A; Scott AJ; Patel K; Thursz M; Lemoine M AIDS; 2017 Jul; 31(11):1621-1632. PubMed ID: 28398960 [TBL] [Abstract][Full Text] [Related]
17. Interference of acetaminophen metabolites in the Glynn-Kendal method for acetaminophen. Alkhayat A Clin Chem; 1986 Dec; 32(12):2208. PubMed ID: 3779990 [No Abstract] [Full Text] [Related]
18. Herbert Milton Nash, MD. Warrior, surgeon and Christian gentleman. Fitchett CW; Old WL Va Med Q; 1995; 122(4):252-4. PubMed ID: 8652682 [No Abstract] [Full Text] [Related]
19. An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare. Persichilli JM; Puro JS MD Advis; 2017; 10(4):33-36. PubMed ID: 29286602 [No Abstract] [Full Text] [Related]
20. Social license as an emergent property of political interactions: response to Kendal and Ford 2017. Garnett ST; Zander KK; Robinson CJ Conserv Biol; 2018 Jun; 32(3):734-736. PubMed ID: 29660179 [No Abstract] [Full Text] [Related] [Next] [New Search]